HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
第2相
実施中（募集終了）
NCT04619004
| 対象疾患 | Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Daiichi Sankyo |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 277 名 |
|---|
| 介入（薬剤） | Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration) |
|---|
| 開始日 | 2021年2月2日 |
|---|
| 完了日 | 2022年11月21日 |
|---|
| 結果公開日 | 2024年4月2日 |
|---|
概要
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)
Data collected from screening until time of disease progression by BICR, death, lost to follow up, study discontinuation, whichever occurs first, assessed up to approximately 21 months · Participants
| Patritumab Deruxtecan 5.6 mg/kg | 64 Participants |
|---|
| Patritumab Deruxtecan Up-Titration | 8 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。